Intravitreal Bevacizumab Treatment in Type 2 Idiopathic Macular Telangiectasia

OBJECTIVES: To evaluate the efficacy of intravitreal bevacizumab treatment in type 2 idiopathic macular telangiectasia (IMT). MATERIALS AND METHODS: Six eyes of 5 patients with type 2 IMT who received intravitreal bevacizumab between 2009 and 2014 were included in this study. All the patients had an...

Descripción completa

Detalles Bibliográficos
Autores principales: Aydoğan, Tuğba, Erdoğan, Gürkan, Ünlü, Cihan, Ergin, Ahmet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Galenos Publishing 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5177783/
https://www.ncbi.nlm.nih.gov/pubmed/28050323
http://dx.doi.org/10.4274/tjo.23921

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5177783/
https://www.ncbi.nlm.nih.gov/pubmed/28050323
http://dx.doi.org/10.4274/tjo.23921

Ejemplares similares